Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Convertible Debt (2018 - 2020)

NovaBridge Biosciences (NBP) has 3 years of Convertible Debt data on record, last reported at $9.5 million in Q3 2020.

  • On a quarterly basis, Convertible Debt changed N/A to $9.5 million in Q3 2020 year-over-year; TTM through Sep 2020 was $9.5 million, a N/A change, with the full-year FY2019 number at $9.8 million, up 1.05% from a year prior.
  • Convertible Debt reached $9.5 million in Q3 2020 per NBP's latest filing, down from $9.8 million in the prior quarter.
  • Over the last five years, Convertible Debt for NBP hit a ceiling of $9.8 million in Q2 2020 and a floor of $9.5 million in Q3 2020.
  • A 3-year average of $9.7 million and a median of $9.7 million in 2018 define the central range for Convertible Debt.
  • On a YoY basis, Convertible Debt climbed as much as 0.18% in 2019 and fell as far as 0.18% in 2019.
  • Tracing NBP's Convertible Debt over 3 years: stood at $9.7 million in 2018, then decreased by 0.18% to $9.7 million in 2019, then fell by 1.41% to $9.5 million in 2020.
  • Business Quant data shows Convertible Debt for NBP at $9.5 million in Q3 2020, $9.8 million in Q2 2020, and $9.7 million in Q4 2019.